2024 “Leveraging Reader Studies for Digital Pathology”, Digital Transformation in Regulatory Science. 14th Global Summit On Regulatory Science (GSRS24) In-Person Annual Conference. Hosted by the US FDA. Little Rock, AK, USA.
2023 “Tumor Infiltrating Lymphocytes: Important until They’re Not”, Invited Speaker, Clinical Science Symposium Discussant, American Society of Clinical Oncology (ASCO), In Person, Chicago, IL, USA.
2023 “Pathology Innovations Collaborative Community (PIcc23): Unlocking the Potential of Digital Pathology and AI through Regulatory Science, Arlington, VA, USA.
2023 “Digital and Computational Pathology”- Expert Panelist. Foundation for the NIH. Biomarkers Consortium. Cancer Steering Committee Scientific Symposium, Bethesda, MD, USA.
2023 Yale New Haven Health, Smilow Cancer Hospital, Panel Moderator, “Smilow Shares Webinar: Perspectives on the USPSTF Breast Screening Recommendations”. New Haven, CT, USA.
2022 “Embracing Complexity in Modern Pathology”, A DAB of Color: Multicolor IHC. Invited Lecturer, Joint Winter Meeting of the Pathological Society and the Royal Society of Medicine. Originally In Person. Changed to Virtual Due to COVID-19 Surge. London, UK.
2022 “Tumor Immune Profiles of Patients with Triple Negative Breast Cancer”, New York University Polyethnic 1000 Consortium Meeting. Cornell University. Ithaca, NY, USA.
2022 “Melanoma Research Alliance Retreat” Session Chair “Special Focus – Highlighting MRA Young Investigator Awardees”, In Person, Washington, DC, USA.
2022 “Image analysis-based TILs measurement predicts breast cancer pCR in the SWOG S0800 neoadjuvant chemotherapy trial”, SWOG Fall Meeting, In Person, Chicago, IL, USA.
2022 “Pre-existing autoantibodies as predictive biomarkers of treatment emergent adverse events”, ALLIANCE Fall Meeting, In Person, Chicago, IL, USA.
2022 MJH Life Sciences CancerNetwork, Speaker “Prediction of pathologic complete response to neoadjuvant chemotherapy in breast cancer (SWOG S0800) using image analysis-based tumor infiltrating lymphocyte measurements”, Chicago, IL, USA.
2022 Molecular differences between younger versus older ER-positive and HER2-negative breast cancers.
2021 “The spatial dynamics of the human tumor immune microenvironment (TIME)”, European Association for Cancer Research, Virtual (Due to COVID-19).
2021 “Artificial intelligence for TIME, tumor immune microenvironment”, Australian Society of Molecular Imaging, Virtual (Due to COVID-19).
2021 “HER2 Heterogeneity”, Translational Science Forum, Invited Lecturer, San Antonio Breast Cancer Symposium. In Person. San Antonio, Texas.
2021 JAX and Yale Cancer Centers Joint Workshop (Organizer; Co-Chair: Speaker): “Deciphering the Tumor Microenvironment Using Advanced Experimental and Analytical Tools”, Farmington, CT, USA.
2021 MedicalXPress -Oncology & Cancer. Study identifies biomarker for breast cancer response to immunotherapy. Vanderbilt University Medical Center.
2021 Ablation of Histone Demethylase KDM5B in Melanoma Augments Anti-Tumor Immunity through Upregulation of Retroelements
2020 “Off the beaten path: Roadmap for identification of immune cells and immune cell clusters in silico using tissue cytometry”, Microscopy & Image Cytometry – From IHC to High-Dimensional Data Mining. Sao Paulo, Brazil.
2020 “Practical approaches for using Tissue Cytometry for clinical and research applications”, TissueGnostics, Asia Pacific, China.
2020 Yale Cancer Center Answers, WNPR, Speaker “Research and work in therapeutic development and health disparities”, New Haven, CT, USA.
2014 Perkin Elmer Annual Imaging Users Group Meeting. Plenary Speaker. Session: New Technologies for Cancer Immunology. “Title: Quantitative Imaging: Transforming Our Approach to Pathology”, Hopkinton, MA, USA.
2013 ISAC CYTO Annual Meeting. Workshop. “Immune Profile Analysis of the Human Lymph Node Microenvironment”, San Diego, CA, USA.